The Effect of Simvastatin and Virgin Coconut Oil (VCO) Combination Therapy as Triglyceride Plasma Lowering Agent in White Dyslipidemic Male Rat (Rattus norvegicus)

Introduction: Dyslipidemia is a major health problem in Indonesia which leads to other diseases. Triglycerides (TG) is one of the increased lipid fractions which is related to dyslipidemia. Simvastatin is the main therapy in Indonesia to lower TG levels. The use of virgin coconut oil (VCO) becomes popular as a blood cholesterol-lowering agent even though the effects on TG level remains elusive. Since there is no empirical evidence VCO as a complementary therapy of simvastatin on TG levels, this experimental trial is conducted to determine the effect of simvastatin and VCO combination therapy on blood TG levels in dyslipidemic male white rats.Methods: 42 white rats (Rattus norvegicus) divided into 5 treatment groups and preliminary test of dyslipidemia. The blood was collected intracardially and TG level was measured by using spectrophotometric methods. Independent variables are simvastatin and VCO and combination therapy while the dependent variable is TG levels of white rats. The data was afterwards analyzed using Mann-Whitney U test.Results: The control group’s triglyceride plasma level, receiving standard diet, is 59±13,4 mg/dl. The VCO-only group shows 72±35,4 mg/dl while simvastatin-only group shows 61,9±22,6 mg/dl triglyceride level. Combination therapy of simvastatin and VCO shows 62,3±31,3 mg/dl (p>0,05).Conclusion: There were no significant differences between groups with control. However,the use of VCO with particular dose and duration of therapy, will significantly decrease triglyceride level in the blood as effective as simvastatin. VCO has no efficacy while used as combination therapy of simvastatin.

Triglyceride and Small Dense LDL-Cholesterol in Patients with Acute Coronary Syndrome

Background: Small dense LDL-cholesterol is an established risk factor for atherosclerosis but is not routinely measured in daily practice. The association between small dense LDL-cholesterol and triglyceride, which in turn is routinely measured, in patients with acute coronary syndrome remains unknown. Methods: Consecutive patients with acute coronary syndrome who were admitted to our institute were prospectively included, and serum samples were obtained on admission. The association between small dense LDL-cholesterol and triglyceride was investigated. Results: Among 55 patients (median 71 years old, 64% men), median (interquartile range) small dense LDL-cholesterol was 23.6 (17.0, 36.0) and triglyceride was 101 (60, 134) mg/dL. Triglyceride level correlated with small dense LDL-cholesterol (r = 0.67, p < 0.001) and was an independent determinant of small dense LDL-cholesterol together with body mass index (p = 0.010 and p = 0.008, respectively). Those with high triglyceride and high body mass index had a 3-fold level of small dense LDL-cholesterol compared with those with low triglyceride and low body mass index (45.8 [35.0, 54.0] mg/dL versus 15.0 [11.6, 23.7] mg/dL, p = 0.001). Conclusions: Triglyceride level was a major determinant of small dense LDL-cholesterol in patients with acute coronary syndrome. Triglyceride level might be a useful and practical biomarker for risk stratification for patients with acute coronary syndrome together with body mass index.

Prediction of Efficacy of Taeumjowi-Tang for Treatment of Metabolic Risk Factors Based on Machine Learning

Herbal medicine is widely prescribed worldwide. To date, however, studies on the prediction of efficacy of herbal medicine based on machine learning have very rarely been reported. The objectives of this study are to predict the efficacy of Taeumjowi-tang (one of herbal medicines) and evaluate the prediction model in treating metabolic abnormalities. Subjects were divided into an improvement group and a non-improvement group based on the difference before and after oral administration of an herbal medicine. Efficacy models of triglyceride level, high-density lipoprotein (HDL) cholesterol level, systolic blood pressure (SBP), and diastolic blood pressure (DBP) were built using a least absolute shrinkage and selection operator (LASSO) based on variables extracted from face shape, face colors, body circumference, questionnaire, voice, and tongue color. In predicting efficacy for four metabolic risk factors, the efficacy model of HDL cholesterol level showed the best the area under the receiver operating characteristic curve (AUC) value among the four models (AUC = 0.785 (confidence interval = 0.693, 0.877)). The AUC value of the efficacy model of triglyceride level was 0.659 (0.551, 0.768). Efficacy models of DBP and SBP showed AUC values of 0.665 (0.551, 0.78) and 0.54 (0.385, 0.694), respectively. The results may provide a clue to predict whether a drug will be effective for each subject with phenotypic information and to reduce the use of an ineffective drug or its side effects.

Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report

Docetaxel (DOC) is one of the most effective agents for breast cancer treatment. Here, we report docetaxel-induced severe hypertriglyceridemia in a patient previously diagnosed with hyperlipidemia and corresponding therapeutic intervention. A postmenopausal woman, with previously controlled hyperlipidemia using rosuvastatin 5 mg daily, was diagnosed with stage IIB breast cancer with human epidermal growth factor receptor-2 overexpression; she received DOC (75 mg/m²), pertuzumab, and trastuzumab treatment as neoadjuvant chemotherapy. The serum triglyceride level was mildly higher than normal, and cholesterol level was normal at baseline. The serum triglyceride level was almost stable after chemotherapy initiation but suddenly increased to grade 3 (770 mg/dL) after the third cycle of the treatment without any symptoms. Sustained-release bezafibrate 400 mg was administered, resulting in a significant decrease to the baseline level; bezafibrate was discontinued on day 28 of the fourth chemotherapy as neoadjuvant chemotherapy was completed. The level was stable around the baseline level during adjuvant chemotherapy with pertuzumab and trastuzumab. Therefore, DOC-induced severe hypertriglyceridemia was strongly indicated in this case. The mechanism underlying the symptoms remains unclear; we speculate that it could be a resultant of a decrease in lipid metabolism as the patient had grade 2 diarrhea. Moreover, her backgrounds, such as mild hypertriglyceridemia, postmenopausal, diabetes, and obesity, in addition to DOC administration might have affected the outcome. Fibrate administration and cessation of treatment were as effective as in previous reports. DOC-induced hypertriglyceridemia presents with the possibility of severe complications. Elucidation of the exact mechanisms and epidemiological features is required for better management.

EFFECTS OF BLENDED RICE BRAN OIL NEPTUNE LIGHT ON THE DYSLIPIDEMIA AMONG OVERWEIGHT AND OBESE ADULTS

Objective: To assessment total cholesterol (TC), LDL-C, HDL, and triglyceride (TG) concentrations changed after using blended rice bran oil Neptune Light among dyslipidemia adults at different categories of obese. Methods: Forty-one adults with dual conditions (dyslipidemia and overweight/obese) from 40 to 60 years old received a 600-700 kcal meal contained 20g/day Neptune Light rice bran oil for 60 days. Fasting blood samples and BMI was collected at baseline and every 30 days of trial. Results: Total cholesterol (TC), LDL-C and TG level declined by 0.5mmol/L (8.5%); 0.49 mmol/L (23.7%) and 0.55 mmol/L (32.0%), respectively after 60 days of intervention. The highest reduction of TC and TG was showed in the pre-obesity group, while the highest LDL-C reduction was shown in the obesity class II group. Conclusion: Using Neptune Light rice bran oil reduced TC, LDL-C and triglyceride level in overweight/obese adults from 40-60 years old after 60 days of intervention.

Adjuvant Supplementation with L-Carnitine in Diabetic Population and its effects on Lipid Parameters

Background: Diabetes is a complicated disease requires continuous clinical care, to govern blood sugar. Aim: To decides the impact of management of L carentin to diabetics at the lipid profile. Methods: This study turned into performed on 120 diabetic Patients had been decided on from endocrinology and diabetes, inside decided on standards. The Patients distributed into three Strata (1st Strata of healthy population and two Strata of patients with diabetes who were on metformin and glibenclamide, one Strata took a L carnitine in a dose of 1000 mg TDS and a Strata dealing with a placebo for a period of ninety days). Results: It is observed those who are on Lcarnitine, confirmed a large discount (p <0.05) with inside the triglyceride level, at the same time as no large adjustments had been located withinside the level of cholesterol and HDL and LDL. Conclusion: These study outcomes that management of L carentin improved profile of lipid in type-2diabetic Patients. Keyword: Dyslipidemia, Diabetes mellitus (DM), l-carnitine (LC).

Comparison of plasmapheresis with medical apheresis in terms of efficacy and cost in the acute treatment of hypertriglyceridemia in children with lipoprotein lipase deficiency

Objectives We aimed to compare plasmapheresis and medical apheresis as lipid-lowering therapies in children with familial lipoprotein lipase (LPL) deficiency. Methods The data of 13 patients who were followed up after a diagnosis of LPL deficiency were retrospectively analyzed. Plasma triglyceride, cholesterol, amylase, and lipase values and complications were recorded before and after each patient underwent plasmapheresis or medical apheresis. Results The mean follow-up period of the patients was 99.64 ± 52.92 months in the medical apheresis group and 118 ± 16.97 months in the plasmapheresis group. While the mean triglyceride level before plasmapheresis was 1,875.38 ± 547.46 mg/dL, it was 617 ± 228.28 mg/dL after plasmapheresis. While the mean triglyceride level before medical apheresis was 1,756.86 ± 749.27 mg/dL, it was found to be 623.03 ± 51.36 mg/dL after medical apheresis. Triglyceride levels were decreased by 59.62% with medical apheresis and 65.57% with plasmapheresis. The cost of treatment for medical apheresis was found to be lower compared to plasmapheresis 296.93 ± 29.94 Turkish lira (USD 43.34 ± 4.01) vs. 3,845.42 ± 156.17 Turkish lira (USD 561.37 ± 20.93; p<0.001). Conclusions Although there is no standardized strategy for the acute treatment of hypertriglyceridemia due to LPL deficiency, medical apheresis is a safe and effective treatment with a low risk of side effects. Unlike plasmapheresis, medical apheresis can be performed in any center, which is another important advantage of the procedure.